Open AccessAmeliorative effects of Cirsium japonicum extract and main component cirsimaritin in mice model of high‐fat diet‐induced metabolic dysfunction‐associated fatty liver disease
Author(s) -
Che Denis Nchang,
Shin Jae Young,
Kang Hyun Ju,
Cho Byoung Ok,
Park Ji Hyeon,
Wang Feng,
Hao Suping,
Sim Jae Suk,
Sim Dong Jun,
Jang Seon Il
Publication year - 2021
Publication title -
food science and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.614
H-Index - 27
ISSN - 2048-7177
DOI - 10.1002/fsn3.2548
Subject(s) - steatosis , cirrhosis , fatty liver , triglyceride , oxidative stress , fibrosis , inflammation , medicine , malondialdehyde , endocrinology , hepatic fibrosis , alanine aminotransferase , biology , disease , cholesterol
The objective of this study was to determine biological effects of Cirsium japonicum extract and its main component cirsimaritin on high‐fat diet (HFD)‐induced metabolic dysfunction‐associated fatty liver disease (MAFLD) in a mouse model. Mice were fed with a HFD to induce MAFLD and simultaneously administered with C . japonicum extract (CJE) or cirsimaritin. Various MAFLD biomarkers were evaluated using biological methods. Results demonstrated that triglyceride, aspartate aminotransferase, alanine aminotransferase, and malondialdehyde levels in the liver of mice were significantly reduced upon administration of CJE or cirsimaritin. Treatment with CJE or cirsimaritin also reduced the severity of liver injury in the experimental mouse model of MAFLD by inhibiting hepatic steatosis, oxidative stress, inflammation, and liver fibrosis. These results demonstrate that CJE and cirsimaritin as its main compound have a preventive action against the progression of hepatic steatosis to fibrosis and cirrhosis. Our study suggests that CJE and cirsimaritin might be promising agents for preventing and/or treating MAFLD.